Please Wait...

OPN / / Osteopontin

Biomarker Therapeutic Areas: 
Biomarker Matrices: 

Identified in bone calcified matrix, Osteopontin (OPN) is also called Bone Sialoprotein I and belongs to the Small Integrin-Binding Ligand, N-linked Glycoprotein (SIBLING) family of protein (Franzen and Heinegard, 1985). OPN contain an RGD motif which allow interaction with integrins and cell surface receptors (Oldberg et al., 1986). OPN interacts with various other partners, can be cleaved by thrombin and in some conditions also by MMP-3 and MMP-7. The resulting fragments have then specific properties which result in modulation of cell migration and adhesion (Bellahcène et al., 2008). Due to its proprieties, OPN is implicated in tumor progression but also in skeletal disorders (Ramchandani and Weber, 2015; Rittling and Chambers, 2004).

Bioclinica Lab employs a manual sandwich immunoassay for the measurement of OPN in plasma.

ADDITIONAL RESOURCES

Biomarker Menu

Download MENU

Molecular Marker Laboratory Services

Download Brochure

Alzheimer's Disease Biomarker Lab Expertise

Download Info Sheet

Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

Today at #SCDM2018 be sure to catch the Technology Ignite session @SCDM_DataDriven where @bioclinica's Clean Patien… https://t.co/HPs0hrLWwO
bioclinica (3 hours ago)
RT @eClinical_Jen: Data Management times are a’changing! AI, Machine Learning, Blockchain, IoT. Leadership Forum at @SCDM_DataDriven #scdm2…
bioclinica (3 hours ago)
RT @virtue_insight: #VIphv We are delighted to announce our new Gold Sponsor @bioclinica for our 16th Pharmacovigilance 2018 https://t.co/h…
bioclinica (5 days ago)
RT @bioclinica: Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas R embra…
bioclinica (5 days ago)
Tackling the costly issue of drug supply waste in clinical trials. Find out how Novo Nordisk & other global pharmas… https://t.co/iW7Q9DfVgQ
bioclinica (2 weeks ago)
Background & key considerations to help #pharma prepare for new FDA blood pressure draft guidance issued in May. Ac… https://t.co/07dJeeD35E
bioclinica (3 weeks ago)

Latest Blogs:

Blood pressure monitor
Prescription box
Latin America: Benefit from the Right Partner
Removing Risk from Clinical Trial Management System (CTMS) Implementations